Published in Pharma Law Weekly, November 2nd, 2004
The patent covers the use of the proprietary cancer therapeutic agents to improve drug delivery to tumors by preventing a cell adhesion protein, known as occludin, from forming cellular barriers within tumors. The patented method may also improve the ability of immune cells to infiltrate tumors.
Cancerous tumors have evolved sophisticated mechanisms for fighting off attempts to kill them, said Orest Blaschuk, PhD,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.